Peptide drug development has made great progress in the last decade thanks to new
production, modification, and analytic technologies. Peptides have been produced and …

Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

This review addresses the interplay between obesity, type 2 diabetes mellitus, and
cardiovascular diseases. It is proposed that obesity, generally defined by an excess of body …

Rigorous evidence identification is essential for systematic reviews and meta‐analyses
(evidence syntheses) because the sample selection of relevant studies determines a …

Type 2 diabetes mellitus (T2DM) continues to be a substantial medical problem due to its
increasing global prevalence and because chronic hyperglycemic states are closely linked …

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …

Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …

A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …